| scholarly article | Q13442814 |
| P50 | author | Elisabet Svenungsson | Q40131460 |
| P2093 | author name string | Aleksandra Antovic | |
| Katarina Bremme | |||
| Maria Sennström | |||
| P2860 | cites work | Diagnosis and Management of the Antiphospholipid Syndrome | Q88785663 |
| A Systematic Review and Meta-Analysis of Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus and Lupus Nephritis | Q22305768 | ||
| The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus | Q28072610 | ||
| Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals | Q28210153 | ||
| The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients | Q28219758 | ||
| A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus | Q28258975 | ||
| Pathophysiology of the antiphospholipid syndrome | Q28267421 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Complement C3 activation is required for antiphospholipid antibody-induced fetal loss | Q33340713 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Early risk factors for pregnancy loss in lupus | Q33370141 | ||
| Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays | Q33404418 | ||
| Neonatal outcome in pregnant patients with antiphospholipid syndrome | Q33418245 | ||
| Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss | Q33428578 | ||
| The Prosser-White oration 1983. Connective tissue disease and the skin | Q33478362 | ||
| The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays | Q33497875 | ||
| Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome | Q33630007 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome | Q33723441 | ||
| The pathogenesis of the antiphospholipid syndrome | Q34332601 | ||
| Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies | Q34424615 | ||
| Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis | Q34963070 | ||
| Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature | Q34977289 | ||
| Subclassification of preeclampsia | Q35196220 | ||
| Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches | Q35621012 | ||
| Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. | Q36222874 | ||
| Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome | Q36242841 | ||
| Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study | Q36421501 | ||
| Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results | Q36472645 | ||
| Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? | Q36785674 | ||
| Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? | Q36832533 | ||
| The antiphospholipid syndrome: still an enigma | Q36928593 | ||
| Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy | Q37137892 | ||
| The role of complement in the antiphospholipid syndrome-associated pathology | Q37344788 | ||
| Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study | Q37420173 | ||
| Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis | Q37811769 | ||
| The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis | Q37855094 | ||
| Physiologic changes during normal pregnancy and delivery | Q38027606 | ||
| Fetal and neonatal effects of anticoagulants used in pregnancy: a review | Q38055192 | ||
| Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature | Q38122121 | ||
| Standardization of antiphospholipid antibody testing--historical perspectives and ongoing initiatives | Q38182509 | ||
| 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome | Q38197819 | ||
| 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends | Q38211487 | ||
| Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. | Q38280730 | ||
| Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review | Q38392607 | ||
| Complement and thrombosis in the antiphospholipid syndrome | Q38916496 | ||
| Pregnancy and Antiphospholipid Syndrome | Q38960542 | ||
| Pregnancy Loss in the Antiphospholipid-Antibody Syndrome — A Possible Thrombogenic Mechanism | Q41099260 | ||
| Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface | Q42084495 | ||
| Statins for the treatment of antiphospholipid syndrome? | Q43275855 | ||
| Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. | Q43626449 | ||
| Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. | Q43841492 | ||
| Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centers | Q45041423 | ||
| Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation | Q45111033 | ||
| Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus | Q45843374 | ||
| Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. | Q46008611 | ||
| Antiphospholipid antibodies in stillbirth | Q47128289 | ||
| HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus | Q48408942 | ||
| Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome | Q49899070 | ||
| Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. | Q50619255 | ||
| Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. | Q50907696 | ||
| Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. | Q51826601 | ||
| Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. | Q52858097 | ||
| A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing. | Q52973341 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| Management of Thrombotic Antiphospholipid Syndrome. | Q53449116 | ||
| Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. | Q53827335 | ||
| Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies. | Q55004116 | ||
| Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients | Q56978037 | ||
| High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome | Q58869486 | ||
| Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol | Q59552940 | ||
| The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review | Q59683885 | ||
| Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia | Q61415575 | ||
| Risk-based secondary prevention of obstetric antiphospholipid syndrome | Q61649509 | ||
| Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome | Q61649548 | ||
| Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach | Q61837755 | ||
| The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population | Q61845862 | ||
| Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study | Q61853553 | ||
| Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies | Q61853563 | ||
| Intrauterine death and circulating anticoagulant ("antithromboplastin") | Q66920894 | ||
| Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies | Q68037355 | ||
| Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study | Q72207320 | ||
| Antiphospholipid antibodies in pregnancy: prevalence and clinical associations | Q72551109 | ||
| Fetal survival after prednisone suppression of maternal lupus-anticoagulant | Q72553985 | ||
| Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo | Q77342565 | ||
| Neuropsychological development of children born to patients with antiphospholipid syndrome | Q80800729 | ||
| Complement activation in patients with primary antiphospholipid syndrome | Q81638094 | ||
| Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression | Q82081772 | ||
| Anticardiolipin and anti-beta2 glycoprotein I antibodies in infants born to mothers with antiphospholipid antibody-positive autoimmune disease: a follow-up study | Q83178270 | ||
| Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | Q83389363 | ||
| Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels | Q83562914 | ||
| Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study | Q84302565 | ||
| The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study | Q84438431 | ||
| Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk | Q86646346 | ||
| Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery | Q86868173 | ||
| Predictors of Pregnancy Outcomes in Patients With Lupus | Q87111843 | ||
| The role of angiogenic biomarkers and uterine artery Doppler in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome | Q88012477 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| P304 | page(s) | e000197 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Lupus science & medicine | Q27725658 |
| P1476 | title | Obstetric antiphospholipid syndrome | |
| P478 | volume | 5 |
| Q90314615 | A rare case of mesenteric vessel thrombosis post caesarian section-An underdiagnosed entity |
| Q92891980 | Association between phospholipid metabolism in plasma and spontaneous preterm birth: a discovery lipidomic analysis in the cork pregnancy cohort |
| Q90115791 | Idiopathic Normal Pressure Hydrocephalus - What We Know |
| Q64112944 | Low molecular weight heparin monotherapy for recurrent abortion with antiphospholipid system: A protocol of a systematic review |
| Q90115787 | Pregnancy Management in Women with Antiphospholidic Syndrome |
Search more.